Article Text

Download PDFPDF
Low rate of intraperitoneal port placement in ovarian cancer patients, a population-based assessment
  1. Lindsey Buckingham1,
  2. Angela Koenig1,
  3. Emily M Ko2,
  4. Colleen M Brensinger3,
  5. Nawar Latif1,
  6. Charles Hummel1,
  7. Xiaochen Zhang2,
  8. Mark A Morgan2,
  9. Robert A Burger2 and
  10. Robert L Giuntoli II2
  1. 1 Gynecologic Oncology, University of Pennsylvania Health System, Philadelphia, Pennsylvania, USA
  2. 2 Division of Gynecologic Oncology, Penn Medicine, Philadelphia, Pennsylvania, USA
  3. 3 University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
  1. Correspondence to Dr Lindsey Buckingham, Gynecologic Oncology, University of Pennsylvania Health System, Philadelphia, PA 19104, USA; linds.k.b{at}


Introduction The National Comprehensive Cancer Network (NCCN) guidelines recommend intraperitoneal chemotherapy in optimally debulked stage III ovarian cancer patients. The objective of this investigation was to determine the rate of intraperitoneal port placement in patients undergoing surgery for ovarian cancer in a national database maintained by the American College of Surgeons.

Method We identified ovarian cancer patients in the National Surgical Quality Improvement Program database from 2006 to 2012. Demographics, comorbidities, operative outcomes, and postoperative complications were abstracted. Descriptive analyses were conducted using Wilcoxon rank-sum and Chi square tests, and multivariate regression models were used to analyze pre-operative and post-operative variables associated with intraperitoneal port placement.

Results We identified 2659 ovarian cancer patients who underwent primary surgical management. Of these patients, only 128 (4.8%) had an intraperitoneal port placed at the time of surgery. In multivariable analyses, intraperitoneal ports were associated with body mass index ≤25, disseminated cancer, later portion of the study period (2009–2012), and operative time >200 min. Intraperitoneal port placement was not associated with any difference in surgical site infection, wound disruption, major postoperative complication, readmission within 30 days, or death within 30 days.

Discussion Recent investigation of practice at NCCN institutions between 2003 and 2012 found only 35% of eligible ovarian cancer patients received intraperitoneal chemotherapy. Using intraperitoneal port placement as a surrogate for intraperitoneal chemotherapy administration, our investigation suggests an even lower rate (4.8%) nationally.

  • ovarian cancer
  • laparotomy
  • operative time

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors LB: primary author, drafting, revision. AK: drafting, revision. EMK: data analysis, drafting, revision. CMB: final data analysis, revision. NL: drafting, revision. CH: drafting, revision. XZ: data abstraction, preliminary analysis, revision. MAM: drafting, revision. RB: drafting, revision. RLG: original concept, drafting, revision.

  • Funding Supported in part by Grant 124268-IRG-78-002-35-IRG from the American Cancer Society and by the George and Emily McMichael Harrison Fund, Penn Presbyterian Harrison Fund of the University of Pennsylvania Hospital Obstetrics and Gynecology Department.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.